证券代码：603883 证券简称：老百姓 老百姓大药房连锁股份有限公司 2024 年半年报解读会纪要 一、会议情况 1.公司参会人员： 总裁 王黎 资管、鹤禧投资、荷荷(北京)私募、永安国富、和谐汇一资管、阿尔法基金、 道翼、大众合邦、大朴资产、大道至诚、大成基金、博远基金、天治基金、三 井住友德思资管、勤远私募、清池资本、青榕资管、青骊投资、平安资管、鹏 扬基金、凯岩投资、凯丰投资、玖鹏资管、景顺长城、景林资管、建信养老 金、嘉实基金、惠理、汇添富、富达基金、敦和资管、Zeal Asset Management Limited 、 UBS 、 Tairen 、 Superstring Capital Management LP 、 Prime Capital Management Company Limited 、 Point72 、 Pinpoint Asset Management Limited 、 OLP Capital Management Limited 、 NSR 、 North Oakridge Asset Management Limited 、 Nomura Asset Manageme ...

老百姓大药房连锁股份有限公司 章 程 （2024年8月修订） 老百姓大药房连锁股份有限公司章程 老百姓大药房连锁股份有限公司章程 第一章 总 则 第一条 为维护老百姓大药房连锁股份有限公司（以下简称"公司"）、股东 和债权人的合法权益，规范公司的组织和行为，根据《中华人民共和国公司法》 （以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券 法》"）和其他有关规定，制订本章程。 第二条 公司系依照《公司法》和其他有关规定成立的股份有限公司。 公司经湖南省商务厅批准，由老百姓大药房连锁有限公司整体变更设立，在湖南 省工商行政管理局注册登记，取得营业执照 ，营业执照号：91430000782853875C。 公司于2017年8月18日经中国证监会核准，以非公开发售方式向特定投资者发行 人民币普通股（A股）17,945,266股。 第三条 公司于2015年4月2日经中国证券监督管理委员会(以下简称"中国证 监会")核准，首次向社会公众发行人民币普通股 6700 万股，于2015年4月23日在上 海证券交易所上市。 第四条 公司注册名称：老百姓大药房连锁股份有限公司。英文名称：LBX Pharmacy ...

证券代码：603883 证券简称：老百姓 公告编号：2024-049 老百姓大药房连锁股份有限公司关于 2024年半年度募集资金存放与实际使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确 性和完整性承担法律责任。 一、募集资金基本情况 （二）募集资金使用和结余情况 截至2024年6月30日，2024年半年度（以下简称"报告期"）使用募集资金 人民币178,213,402元，公司累计使用募集资金人民币1,351,319,106元，公司 尚未投入募投项目的募集资金余额（募投项目尾款）共计人民币386,858,696元 （含募集资金银行存款产生的利息并扣除银行手续费支出），其中募集资金存 放专项账户的余额人民币86,858,696元，暂时补充流动资金人民币300,000,000 元。 二、募集资金管理情况 为规范公司募集资金管理和使用，保护投资者权益，按照《中华人民共和国公 司法》《中华人民共和国证券法》《上海证券交易所股票上市规则》《上市公司监 管指引第2号——上市公司募集资金管理和使用的监管要求（2022年修订）》和《 上海证券交易所 ...

关于 2024 年半年度主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性 和完整性承担法律责任。 根据上海证券交易所发布的上市公司分行业信息披露指引及《关于做好主板 上市公司2024年半年度报告披露工作的重要提醒》等相关要求，现将老百姓大药 房连锁股份有限公司（以下简称"公司"）2024年半年度主要经营数据披露如下： 一、报告期末主要经营数据 1、主要会计数据 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比上年同期 增减变动幅度(%) | | | --- | --- | --- | --- | | 营业收入 | 10,939,662,786 | | 1.19 | | 归属于上市公 | | | | | 司股东的净利 | 502,704,433 | | (2.05) | | 润 | | | | | 归属于上市公 | | | | | 司股东的扣除 | 481,786,017 | | (1.79) | | 非经常性损益 | | | | | 的净利润 | | | | | 经营活动产生 | | | | | 的现金流量净 | 6 ...

证券代码：603883 证券简称：老百姓 公告编号：2024-047 老百姓大药房连锁股份有限公司 关于 2024 年半年度利润分配预案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性 和完整性承担法律责任。 重要内容提示: ●每股派发现金红利 0.3307 元（含税），不进行资本公积转增股本，不送 红股。 ●本次利润分配、公积金转增股本以实施权益分派股权登记日总股本为基 数，具体日期将在权益分派实施公告中明确。 ●在实施权益分派的股权登记日前公司总股本发生变动的，拟维持分配总额 不变，相应调整每股分配比例，并将在相关公告中披露。 一、利润分配预案内容 老百姓大药房连锁股份有限公司（以下简称"公司"）2024 年半年度实现合 并口径归属于上市公司股东净利润 502,704,433 元，截至 2024 年 6 月 30 日，母 公司报表累计未分配利润为 1,115,023,555 元。为践行"以投资者为本"的发展 理念，落实"提质增效重回报"行动方案，增强投资者获得感，维护公司全体股 东利益，积极回报广大股东，经公司控股股东老百姓医药集团有限公 ...

Financial Performance - The company's operating revenue for the first half of 2024 was CNY 10,939,662,786, representing a 1.19% increase compared to CNY 10,810,860,321 in the same period last year [22]. - The net profit attributable to shareholders of the listed company decreased by 2.05% to CNY 502,704,433 from CNY 513,245,443 year-on-year [22]. - The net cash flow from operating activities dropped significantly by 41.04%, amounting to CNY 611,485,210 compared to CNY 1,037,071,402 in the previous year [22]. - The total assets of the company at the end of the reporting period were CNY 21,029,704,173, a decrease of 0.95% from CNY 21,230,999,976 at the end of the previous year [22]. - The net assets attributable to shareholders of the listed company increased by 1.96% to CNY 6,832,734,353 from CNY 6,701,235,576 at the end of the previous year [22]. - The basic earnings per share for the first half of 2024 were CNY 0.66, down 2.06% from CNY 0.68 in the same period last year [23]. - The weighted average return on net assets decreased by 1.63 percentage points to 7.22% compared to 8.85% in the previous year [23]. Dividend and Shareholder Returns - The company plans to distribute a cash dividend of RMB 3.307 per 10 shares, totaling RMB 251,408,449.24, which accounts for 50.01% of the net profit attributable to shareholders for the first half of 2024 [5]. - The report does not include any plans for capital reserve transfers or stock dividends [5]. - The company plans to distribute a cash dividend of 0.3307 CNY per share, amounting to a total of 251,408,449.24 CNY, which represents 50.01% of the net profit attributable to shareholders for the first half of 2024 [111]. Risk Management - The report indicates that there are no significant risks impacting the company's operations during the reporting period [7]. - The company has outlined potential risks and corresponding mitigation strategies in the management discussion section [7]. - The company emphasizes the importance of investor awareness regarding the risks associated with forward-looking statements [6]. - The company is focused on mitigating risks associated with market competition and acquisition performance through improved management systems and strategic planning [104]. Corporate Governance - The board of directors and management confirm the accuracy and completeness of the financial report, ensuring no misleading statements or omissions [3]. - All board members attended the board meeting, ensuring collective responsibility for the report's content [4]. - The company has established a clear governance structure, ensuring that all board and shareholder meetings are conducted independently [125]. - The company has committed to adhering to the regulations set forth by the China Securities Regulatory Commission and the Shanghai Stock Exchange, ensuring fair treatment of all shareholders [126]. Market Expansion and Strategy - The company is focusing on expanding its market presence and enhancing customer engagement through innovative service models like DTP and SCRM [16]. - The company plans to continue investing in new product development and technology to improve operational efficiency and customer satisfaction [16]. - The company is exploring potential mergers and acquisitions to strengthen its market position and expand its service offerings [16]. - The company is actively exploring new retail and prescription drug sectors, aiming to become a technology-driven health service platform [27]. Operational Efficiency - The company achieved a gross margin of 34.32%, an increase of 1.6 percentage points compared to the previous period [66]. - The company’s operating efficiency showed a daily average sales per square meter of 48 CNY across all store types [91]. - The average preparation cycle for new direct-operated stores was reduced to 41 days, a decrease of 9 days compared to the first half of 2023 [58]. - The company’s digital transformation strategy focuses on data-driven management, enhancing operational efficiency and optimizing business processes [61]. Social Responsibility and Sustainability - The company invested 1.79 million CNY in social welfare and charity projects in the first half of 2024, including a cash donation of 700,000 CNY to the Hunan Provincial Impact Public Welfare Foundation [119]. - The company has committed to social responsibility initiatives, focusing on community health management and rural revitalization efforts [119]. - The company plans to install over 5,000 square meters of solar photovoltaic panels, expected to generate 900,000 kWh annually, with construction preparations underway [116]. - The company has recycled approximately 2 tons of cardboard by reusing around 2,000 boxes in the first half of 2024 [116]. Financial Independence and Compliance - The company has committed to not engaging in any business that constitutes substantial competition with its operations, ensuring compliance with relevant regulations [125]. - The company has established an independent financial department and accounting system, ensuring that financial decisions are made independently without interference from external entities [125]. - The company has confirmed that it will not use its assets as collateral for its own debts, maintaining financial independence [125]. - The company has committed to ensuring its independence post-transaction, maintaining separation in personnel, assets, finance, and operations [127]. Shareholder Structure and Changes - The total number of shareholders as of the reporting period is 23,118 [160]. - The top ten shareholders hold a total of 198,564,175 shares, representing 26.12% of the total shares outstanding [161]. - The second largest shareholder, Zexing Investment Co., Ltd., holds 168,013,035 shares, accounting for 22.10% [161]. - There were no changes in the actual controller or major shareholders during the reporting period [166]. Research and Development - The company's research and development expenses decreased by 8.20% to CNY 419,905 compared to CNY 457,430 in the previous year [95]. - Research and development expenses for the first half of 2024 were CNY 419,905, a slight decrease from CNY 457,430 in the same period of 2023 [177]. Legal and Compliance Matters - The company has not engaged in any significant litigation or arbitration matters during the reporting period [142]. - The company has maintained a good integrity status, with no significant debts or court judgments unfulfilled during the reporting period [142]. - The company has confirmed that all commitments related to refinancing and stock incentives have been fulfilled as of the specified dates [124].

证券代码：603883 证券简称：老百姓 公告编号：2024-051 老百姓大药房连锁股份有限公司 关于召开 2024 年第二次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一) 股东大会类型和届次 2024 年第二次临时股东大会 召开的日期时间：2024 年 9 月 18 日 14 点 30 分 召开地点：长沙市开福区青竹湖路 808 号老百姓 15 楼会议室 股东大会召开日期：2024年9月18日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 (二) 股东大会召集人：董事会 (三) 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 (四) 现场会议召开的日期、时间和地点 (五) 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2024 年 9 月 18 日至 2024 年 9 月 18 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 关于控股股东部分股份解除质押的公告 重要内容提示： ●截至本公告日，老百姓大药房连锁股份有限公司（以下简称"公司"）控股股 东老百姓医药集团有限公司（以下简称"医药集团"）持有公司股份 198,564,175 股， 占公司股份总数的 26.12%；本次解除股份质押 28,730,000 股后，医药集团持有公司股 份累计质押数量为 107,454,000 股，占其持股总数的 54.12%，占公司总股本的 14.13%。 证券代码：603883 证券简称：老百姓 公告编号：2024-043 老百姓大药房连锁股份有限公司 | 占公司总股本比例（%） | 3.78 | | | | | --- | --- | --- | --- | --- | | 解除质押时间 | 2024 年 8 | 13 | 月 | 日 | | 持股数量（股） | 198,564,175 | | | | | 持股比例（%） | 26.12 | | | | | 剩余被质押股份数量(股） | 107,454,000 | ...

Summary of Conference Call Records Company and Industry Overview - The company discussed its franchise business development, emphasizing its role as a "second curve" for long-term growth, focusing on "win-win and altruism" to support franchisees in enhancing store operations [1] - The company operates in the pharmaceutical retail industry, facing stricter regulatory environments and increased market price transparency, which poses challenges for small chain and independent pharmacies [1][2] Key Points and Arguments Franchise Business Development - The total number of franchise stores has exceeded 5,000, with annual distribution revenue growing from nearly 600 million to 2.2 billion from 2019 to 2023, reflecting a compound annual growth rate of approximately 38.38% [1] - The company employs a "seven unification" strategy to ensure high standards in management and operations, which includes unified branding, management systems, training, procurement, financial management, and pharmaceutical service standards [1] Industry Policy Impact - The tightening of regulations and increased price transparency is expected to benefit larger chain pharmacies with stronger compliance, management, product selection, and service capabilities, leading to accelerated market concentration [2] - The company has established a strict compliance control system and enhanced process management through systematic and digital means [2][3] Market Expansion and Downstream Strategy - The company is focusing on expanding its store network in 11 advantageous provinces and actively developing lower-tier markets, which is seen as both a strategic necessity and a social responsibility [3] - As of Q1 2024, 76% of the company's stores are located in prefecture-level cities and below, with 78% of new stores in 2023 situated in these areas [3] Chronic Disease Management and Health Consultation Innovations - The company established a "Chronic Disease and Health Management Center" in 2018, providing personalized health management services for chronic disease members [4] - By Q1 2024, the company has built a database for over 14 million individuals, conducted over 70 million self-tests, and held 24,000 educational sessions [4] Brand Development - The company is actively engaging in brand activities and content creation to enhance brand visibility and user engagement, producing over 60 health science and brand communication pieces in Q1 [5] - Brand activities are centered around user needs, with campaigns like "Family Flavor, Healthy Year" and "Painless China, Beautiful Occurrence" aimed at increasing brand loyalty [5] Additional Important Content - The company leverages its strong brand influence and advanced digital capabilities to empower franchise stores, ensuring quality and efficiency in operations [1] - The focus on chronic disease management reflects the growing demand due to an aging population and increasing chronic disease prevalence [4]

证券代码：603883 证券简称：老百姓 老百姓大药房连锁股份有限公司 机构投资者交流活动会议纪要（2024.7） 一、会议情况 （一）会议时间：2024 年 7 月份 （二）会议形式：现场/线上会议 （三）会议地点：公司会议室/券商策略会/线上会议等 （四）参会人员： 1.公司参会人员： 董事会秘书 冯诗倪 证券事务代表 刘遐迩 2.机构参会人员： 中信证券、中欧基金、淡水泉、中银国际、汇丰晋信、惠升基金、国华兴益、德 邦证券、勤远私募、途灵资管、君和立成、东吴基金、农银汇理、鑫元基金、光 大保德信基金、泓德基金、兴业基金、汇添富基金、博道基金、长江证券、上银 基金、弘尚资管、光大证券、东吴证券、广发证券、易方达基金、嘉实基金、平 安养老、天弘基金、华福证券、招商证券、东海证券、瑞银、凯岩投资、长江证 券、奶酪基金、富国基金、高盛、凯石资本、汇丰前海证券、景泰利丰、Mondrian、 东北证券、银河证券、民生证券、大和证券、国盛证券、Matthews Asia、华夏 久盈等 49 位机构投资者（排名不分先后）。 二、主要内容 投资者提问 问题 1：公司目前加盟业务发展如何？有什么特点？ 回答：加盟业务是公司 ...